145 related articles for article (PubMed ID: 10454504)
21. Pharmacology of [3H]prostaglandin E1/[3H]prostaglandin E2 and [3H]prostaglandin F2alpha binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data.
Sharif NA; Xu SX; Williams GW; Crider JY; Griffin BW; Davis TL
J Pharmacol Exp Ther; 1998 Aug; 286(2):1094-102. PubMed ID: 9694973
[TBL] [Abstract][Full Text] [Related]
22. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.
Sharif NA; Kelly CR; Crider JY
J Ocul Pharmacol Ther; 2002 Aug; 18(4):313-24. PubMed ID: 12222762
[TBL] [Abstract][Full Text] [Related]
23. Thromboxane prostanoid receptor activation amplifies airway stretch-activated contractions assessed in perfused intact bovine bronchial segments.
Hernandez JM; Janssen LJ
J Pharmacol Exp Ther; 2011 Oct; 339(1):248-56. PubMed ID: 21768224
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of prostaglandin synthesis in newborn pigs increases cerebral microvessel prostaglandin F2 alpha and prostaglandin E2 receptors, their second messengers and vasoconstrictor response to adult levels.
Li DY; Abran D; Peri KG; Varma DR; Chemtob S
J Pharmacol Exp Ther; 1996 Jul; 278(1):370-7. PubMed ID: 8764372
[TBL] [Abstract][Full Text] [Related]
25. Functional pharmacology of human prostanoid EP2 and EP4 receptors.
Wilson RJ; Rhodes SA; Wood RL; Shield VJ; Noel LS; Gray DW; Giles H
Eur J Pharmacol; 2004 Oct; 501(1-3):49-58. PubMed ID: 15464062
[TBL] [Abstract][Full Text] [Related]
26. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells.
Casimir DA; Miller CW; Ntambi JM
Differentiation; 1996 Jul; 60(4):203-10. PubMed ID: 8765050
[TBL] [Abstract][Full Text] [Related]
27. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
Sharif NA; Crider JY; Xu SX; Williams GW
J Pharmacol Exp Ther; 2000 May; 293(2):321-8. PubMed ID: 10772998
[TBL] [Abstract][Full Text] [Related]
28. Radioligand binding analysis of receptor subtypes in two FP receptor preparations that exhibit different functional rank orders of potency in response to prostaglandins.
Woodward DF; Fairbairn CE; Krauss AH; Lawrence RA; Protzman CE
J Pharmacol Exp Ther; 1995 Apr; 273(1):285-7. PubMed ID: 7714778
[TBL] [Abstract][Full Text] [Related]
29. Cat iris sphincter smooth-muscle contraction: comparison of FP-class prostaglandin analog agonist activities.
Sharif NA; Kaddour-Djebbar I; Abdel-Latif AA
J Ocul Pharmacol Ther; 2008 Apr; 24(2):152-63. PubMed ID: 18355130
[TBL] [Abstract][Full Text] [Related]
30. Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors.
Chen J; Lu RT; Lai R; Dinh T; Paul D; Venadas S; Wheeler LA
Curr Eye Res; 2009 Mar; 34(3):184-95. PubMed ID: 19274525
[TBL] [Abstract][Full Text] [Related]
31. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation.
Behm DJ; Ogbonna A; Wu C; Burns-Kurtis CL; Douglas SA
J Pharmacol Exp Ther; 2009 Jan; 328(1):231-9. PubMed ID: 18836067
[TBL] [Abstract][Full Text] [Related]
32. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors.
Kim HJ; Chung JI; Lee SH; Jung YS; Moon CH; Baik EJ
Brain Res; 2008 Feb; 1193():153-61. PubMed ID: 18178179
[TBL] [Abstract][Full Text] [Related]
33. Response of rat thoracic aorta to F(2)-isoprostane metabolites.
Cracowski JL; Camus L; Durand T; Devillier P; Guy A; Hardy G; Stanke-Labesque F; Rossi JC; Bessard G
J Cardiovasc Pharmacol; 2002 Mar; 39(3):396-403. PubMed ID: 11862119
[TBL] [Abstract][Full Text] [Related]
34. E-ring isoprostane augments cholinergic neurotransmission in bovine trachealis via FP prostanoid receptors.
Paredes C; Tazzeo T; Janssen LJ
Am J Respir Cell Mol Biol; 2007 Dec; 37(6):739-47. PubMed ID: 17630320
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation.
Woodward DF; Burke JA; Williams LS; Palmer BP; Wheeler LA; Woldemussie E; Ruiz G; Chen J
Invest Ophthalmol Vis Sci; 1989 Aug; 30(8):1838-42. PubMed ID: 2759797
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of the prostanoid DP receptor in human myometrium.
Fernandes B; Crankshaw D
Eur J Pharmacol; 1995 Sep; 283(1-3):73-81. PubMed ID: 7498323
[TBL] [Abstract][Full Text] [Related]
37. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
38. E-ring 8-isoprostanes are agonists at EP2- and EP4-prostanoid receptors on human airway smooth muscle cells and regulate the release of colony-stimulating factors by activating cAMP-dependent protein kinase.
Clarke DL; Belvisi MG; Hardaker E; Newton R; Giembycz MA
Mol Pharmacol; 2005 Feb; 67(2):383-93. PubMed ID: 15528403
[TBL] [Abstract][Full Text] [Related]
39. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
